Vice President, Drug Substance Technologies, Amgen
Rohini Deshpande leads the Amgen Massachusetts (AMA) site, which sits in the heart of the Cambridge biotech ecosystem. As Site Head, Rohini and her leadership team work to maximize the strategic potential of AMA, further building capabilities at the site to be a center of excellence for Amgen Operations.
In addition to her role as Site Head, Rohini also serves as Vice President, Drug Substance Technologies. Rohini’s Drug Substance Process Development team develops and transfers Drug Substance processes to Amgen manufacturing sites to ensure reliable supply, and advance next-generation manufacturing technologies. Rohini’s team has presence in several US sites (Thousand Oaks, Cambridge, Rhode Island, Puerto Rico), Singapore, and Germany. Prior to this role, Rohini served as Vice President, Attribute Sciences, in which she established an analytical organization with end-to-end capabilities for a diverse portfolio from pre-pivotal to commercial stages. Rohini’s team developed attribute-focused capabilities across seven Amgen sites and established novel strategies and technologies to achieve specific quality target product profiles for products and materials. During her tenure, Attribute Sciences implemented phase appropriate release testing at the pre-pivotal phase to reduce timelines and in the commercial phase established a unified approach to method development and transfer through method stewardship to improve reliability in collaboration with Quality. Since joining Amgen in 1997, Rohini has held numerous positions of increasing responsibility and leadership, including Director of Cell Sciences & Technology and Executive Director Drug Substance. Over the years, Rohini has also led teams and initiatives that advanced the Molecule Assessment Process, Platform Evolution, Fast-to-Patient Approach and Manufacturing of the Future. Prior to joining Amgen, Rohini was a postdoctoral fellow at UCLA and University of Michigan and earned a Ph.D. in Biology from SUNY Binghamton.